Trial
NCT05766514
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Florida
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Cladribine
Why stopped
Study disapproved by internal scientific review committee on re-review; study will no longer move forward
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-22